Compare

ChemoMetec A/S/€CHEMM

1D1W1M3M6MYTD1Y5YMAX

About ChemoMetec A/S

ChemoMetec A/S is engaged in the development, manufacturing, and marketing of analytical instruments used for counting and analyzing cells in a variety of applications across biotechnology, pharmaceuticals, and academic research sectors. The company’s main product lines include automated cell counters and analyzers, such as the NucleoCounter series. Founded in 1997, ChemoMetec is headquartered in Allerod, Denmark. The company is noted for its focus on innovation in cell counting technology, providing precise and user-friendly solutions that facilitate laboratory workflows and enhance data accuracy. Its strategic position in the analytical instruments industry is strengthened by its commitment to quality and reliability in measurement instrumentation.
Ticker
€CHEMM
Sector
Health
Primary listing
XGAT
Employees
174
Headquarters
Allerød, Denmark
Website
chemometec.com

ChemoMetec A/S Metrics

BasicAdvanced
€1.6B
61.95
€1.55
1.39
-

What the Analysts think about ChemoMetec A/S

Analyst ratings (Buy, Hold, Sell) for ChemoMetec A/S stock.
Analyst projections of the future price of ChemoMetec A/S stock.

Bulls say / Bears say

After stronger-than-expected first-quarter instrument demand, led by the NC-203, ChemoMetec raised its 2026/27 revenue guidance to DKK 560–590 million and EBITDA guidance to DKK 330–345 million. This is a fresh sign that the new product cycle is gaining traction. (ChemoMetec)
For 2025/26, EBITDA rose 9% to DKK 281.3 million and the margin improved to 55%, while XcytoMatic sales more than doubled. That shows the company can grow profitably as its newer instruments gain sales. (ChemoMetec)
ChemoMetec’s Roche collaboration will connect its XM30 cell analyser with Roche’s Cedex Bio Analyzer, with both companies committing to promote the combined solution. Successful integration could help ChemoMetec reach more bioprocessing customers. (ChemoMetec)
Consumables revenue fell 4% in 2025/26, and management linked weaker demand to lower activity among cell-therapy customers and the departure of some large players. That puts pressure on a recurring revenue stream while end-market activity remains uneven. (StockAnalysis)
Management says customer validations can take years and its near-term visibility is limited; potential sales from Roche, Tecan and Hamilton collaborations were not included in its original annual guidance. Delays could therefore leave the growth outlook harder to deliver or time. (StockAnalysis)
The growth plan requires substantial investment: ChemoMetec expects about DKK 120 million of capital spending in 2026/27, after spending about DKK 100 million on growth initiatives in 2025/26. Those outlays may weigh on cash generation if automation and software adoption takes longer than expected. (StockAnalysis, ChemoMetec)
Data summarised monthly by Lightyear AI. Last updated on 1 Nov 2026.

ChemoMetec A/S Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

ChemoMetec A/S Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.